Brenner Todd, Kuo Albert, Sperna Weiland Christina J, Kamal Ayesha, Elmunzer B Joseph, Luo Hui, Buxbaum James, Gardner Timothy B, Mok Shaffer S, Fogel Evan S, Phillip Veit, Choi Jun-Ho, Lua Guan W, Lin Ching-Chung, Reddy D Nageshwar, Lakhtakia Sundeep, Goenka Mahesh K, Kochhar Rakesh, Khashab Mouen A, van Geenen Erwin J M, Singh Vikesh K, Tomasetti Cristian, Akshintala Venkata S
Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Gastrointest Endosc. 2025 Jan;101(1):129-138.e0. doi: 10.1016/j.gie.2024.08.009. Epub 2024 Aug 13.
A robust model of post-ERCP pancreatitis (PEP) risk is not currently available. We aimed to develop a machine learning-based tool for PEP risk prediction to aid in clinical decision making related to periprocedural prophylaxis selection and postprocedural monitoring.
Feature selection, model training, and validation were performed using patient-level data from 12 randomized controlled trials. A gradient-boosted machine (GBM) model was trained to estimate PEP risk, and the performance of the resulting model was evaluated using the area under the receiver operating curve (AUC) with 5-fold cross-validation. A web-based clinical decision-making tool was created, and a prospective pilot study was performed using data from ERCPs performed at the Johns Hopkins Hospital over a 1-month period.
A total of 7389 patients were included in the GBM with an 8.6% rate of PEP. The model was trained on 20 PEP risk factors and 5 prophylactic interventions (rectal nonsteroidal anti-inflammatory drugs [NSAIDs], aggressive hydration, combined rectal NSAIDs and aggressive hydration, pancreatic duct stenting, and combined rectal NSAIDs and pancreatic duct stenting). The resulting GBM model had an AUC of 0.70 (65% specificity, 65% sensitivity, 95% negative predictive value, and 15% positive predictive value). A total of 135 patients were included in the prospective pilot study, resulting in an AUC of 0.74.
This study demonstrates the feasibility and utility of a novel machine learning-based PEP risk estimation tool with high negative predictive value to aid in prophylaxis selection and identify patients at low risk who may not require extended postprocedure monitoring.
目前尚无完善的内镜逆行胰胆管造影术后胰腺炎(PEP)风险模型。我们旨在开发一种基于机器学习的PEP风险预测工具,以辅助与围手术期预防措施选择和术后监测相关的临床决策。
使用来自12项随机对照试验的患者水平数据进行特征选择、模型训练和验证。训练一个梯度提升机(GBM)模型来估计PEP风险,并使用接受者操作特征曲线下面积(AUC)和5折交叉验证来评估所得模型的性能。创建了一个基于网络的临床决策工具,并使用约翰霍普金斯医院在1个月内进行的ERCP数据进行了一项前瞻性试点研究。
GBM共纳入7389例患者,PEP发生率为8.6%。该模型基于20个PEP风险因素和5种预防干预措施(直肠非甾体抗炎药[NSAIDs]、积极补液、直肠NSAIDs与积极补液联合、胰管支架置入以及直肠NSAIDs与胰管支架置入联合)进行训练。所得GBM模型的AUC为0.70(特异性65%,敏感性65%,阴性预测值95%,阳性预测值15%)。前瞻性试点研究共纳入135例患者,AUC为0.74。
本研究证明了一种新型的基于机器学习的PEP风险评估工具的可行性和实用性,该工具具有较高的阴性预测值,有助于预防措施的选择,并识别可能不需要延长术后监测的低风险患者。